Darolutamide + ADT in combination with docetaxel is to be used to treat patients (on the NHS) with metastatic hormone-sensitive prostate cancer (mHSPC) and will be immediately available in England for eligible patients following marketing authorisation from the MHRA.
pharmaphorum.com/news/mhra-...
I will be talking to my Uro-Onc care team about this.
Great news, I hope the rest of Europe will follow!
Hi. Thanks for the post, I also saw the Times article. Are you sure about the hormone sensitive requirement ? When I look up Darolutamide on the prostatecanceruk.org website, here is an excerpt:
“Darolutamide is a treatment for prostate cancer that has stopped responding to other types of hormone therapy, but has not yet spread to other parts of the body. You may hear this called non-metastatic castrate-resistant (or hormone-relapsed) prostate cancer (nmCRPC).”
This needs updating to cover metastatic pc in light of the trial results but does not seem to be restricted to hormone sensitive. Would appreciate your thoughts.
If you read the article, you'll see it's not restricted to mHSPC but has been newly licenced for it. It was licenced for nmCRPC in 2020:
"Darolutamide + ADT in combination with docetaxel is to be used to treat patients with metastatic hormone-sensitive prostate cancer (mHSPC) and will be immediately available in England for eligible patients following marketing authorisation from the MHRA. This follows the initial licence for treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in 2020."
Thanks for the clarification. I had thought you were referring to the Times of London article, which does not contain the licensing information in your link. Unfortunately for me it seems this therapy is not licenced for mCRPC, which is where I’m at.
Odd indeed. I will talk to the oncologist about it. But this latest news seems to fit your profile very well. Good luck with it.
Triplet therapy question
PSA rise after triplet therapy 
